There is an active debate about Nvidia’s competitive moat. Some say there’s a prevailing perception of a ‘safe’ choice when investing billions in a technology, in which the return is still uncertain.
Read more here.
There is an active debate about Nvidia’s competitive moat. Some say there’s a prevailing perception of a ‘safe’ choice when investing billions in a technology, in which the return is still uncertain.
Read more here.
![[OurCrowd in The Times of Israel] Nobel laureate Prof. Aaron Ciechanover to discuss advances in precision medicine](https://blog.ourcrowd.com/wp-content/themes/Extra/images/post-format-thumb-text.svg)
